Hemorheological Alterations in Patients with Heart Failure with Reduced Ejection Fraction Treated by Resveratrol

Autor: Miklos Rabai, Roland Gal, Tamas Habon, Dora Praksch, Peter Kenyeres, Robert Halmosi, Kalman Toth
Rok vydání: 2020
Předmět:
0301 basic medicine
Erythrocyte Aggregation
Male
medicine.medical_specialty
Time Factors
Article Subject
RM1-950
030204 cardiovascular system & hematology
Hematocrit
Resveratrol
Erythrocyte aggregation
Ventricular Function
Left
Microcirculation
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Double-Blind Method
Internal medicine
Diseases of the circulatory (Cardiovascular) system
Erythrocyte deformability
Medicine
Humans
Pharmacology (medical)
Aged
Pharmacology
Heart Failure
Hungary
Ejection fraction
Exercise Tolerance
medicine.diagnostic_test
business.industry
Cardiovascular Agents
Stroke Volume
General Medicine
Middle Aged
medicine.disease
030104 developmental biology
Treatment Outcome
chemistry
RC666-701
Heart failure
Cardiology
Female
Therapeutics. Pharmacology
Cardiology and Cardiovascular Medicine
business
Perfusion
Research Article
Zdroj: Cardiovascular Therapeutics
Cardiovascular Therapeutics, Vol 2020 (2020)
ISSN: 1755-5922
Popis: Objectives. Several beneficial effects of resveratrol have already been published. This study evaluated the effect of resveratrol on the hemorheological parameters in patients with heart failure with reduced ejection fraction. Methods. In our double-blind, placebo-controlled human clinical trial, we enrolled 60 outpatients with heart failure. Patients were randomized into two groups: receiving either 100 mg resveratrol capsule daily or placebo for 3 months. Hematocrit was determined by microhematocrit centrifuge. Plasma and whole blood viscosity was evaluated by capillary viscometer. Erythrocyte aggregation was measured by both LORCA and Myrenne aggregometers. LORCA ektacytometer was used for measuring erythrocyte deformability. Exercise capacity was assessed by a 6-minute walk test. Results. Resveratrol treatment did not have any significant effect on hematocrit and viscosity. The erythrocyte deformability also remained unchanged. However, significant improvement of red blood cell aggregation was observed in the resveratrol group compared to baseline after 3 months. Furthermore, positive correlation was found between the exercise capacity and the hemorheological properties (Hct, WBV, and RBC aggregation and deformability) as well. Conclusion. These findings indicate that resveratrol can significantly reduce red blood cell aggregation, which may positively influence microcirculation, which may contribute to the improvement of tissue perfusion and oxygen supply in heart failure.
Databáze: OpenAIRE
Externí odkaz: